Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03211507
Other study ID # 16SM3627
Secondary ID
Status Completed
Phase
First received
Last updated
Start date May 1, 2017
Est. completion date October 5, 2019

Study information

Verified date December 2019
Source Imperial College London
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

A case-control study to investigate whether job exposures are an under-recognized cause of idiopathic pulmonary fibrosis (IPF) using an interview to collect information about previous jobs and a blood test to investigate genetic susceptibility.


Description:

Idiopathic pulmonary fibrosis (IPF) is a scarring lung disease. It damages the air sacs that allow oxygen to be transferred into the blood and transported to vital organs. These changes make people with IPF cough and feel short of breath. It not known what causes the damage. People who get IPF are usually older than 40Íž it's a very serious illness that cannot be cured and gets worse over time. Statistics show that IPF is becoming more common in the UK but it's not known why. It can be difficult for doctors to tell if someone has IPF or another disease called asbestosis.


Recruitment information / eligibility

Status Completed
Enrollment 960
Est. completion date October 5, 2019
Est. primary completion date October 5, 2019
Accepts healthy volunteers No
Gender Male
Age group N/A and older
Eligibility For cases

Inclusion Criteria:

- New diagnosis of IPF between February 2017 and October 2019

Exclusion Criteria:

- Unable to give informed consent

- Ever worked outside of the UK

For controls

Inclusion Criteria:

- New outpatient department attendee between February 2017 and October 2019

Exclusion Criteria:

- Unable to give informed consent

- Ever worked outside of the UK (does not include work outside the UK by members of the armed forces or merchant navy)

- Diagnosis of IPF

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Computer-assisted telephone interview
Occupational history
Genetic:
Genetic analysis
To include analysis of known susceptibility markers

Locations

Country Name City State
United Kingdom Imperial Healthcare NHS Trust London

Sponsors (23)

Lead Sponsor Collaborator
Imperial College London Aberdeen Royal Infirmary, Aintree University Hospitals NHS Foundation Trust, Glasgow Royal Infirmary, Guy's and St Thomas' NHS Foundation Trust, Heart of England NHS Foundation Trust, Imperial College Healthcare NHS Trust, Morriston Hospital, Newcastle-upon-Tyne Hospitals NHS Trust, Norfolk and Norwich University Hospitals NHS Foundation Trust, North Bristol NHS Trust, Nottingham University Hospitals NHS Trust, Papworth Hospital NHS Foundation Trust, Portsmouth Hospitals NHS Trust, Royal Devon and Exeter NHS Foundation Trust, Royal Infirmary of Edinburgh, Taunton and Somerset NHS Foundation Trust, The Leeds Teaching Hospitals NHS Trust, University Hospital Birmingham NHS Foundation Trust, University Hospital of South Manchester, University Hospital Southampton NHS Foundation Trust, Wellcome Trust, Worcestershire Acute Hospitals NHS Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Association between asbestos exposure and IPF estimated using logistic regression for any vs no asbestos exposure and adjusting for age and smoking status 2 years
Secondary Dose-response relationship between asbestos exposure and IPF estimated using logistic regression for categories of cumulative exposure and adjusting for age and smoking status 2 years
Secondary Gene-environment interaction (for MUC5B rs35705950 and asbestos exposure) odds ratio. MUC5B rs35705950 and asbestos exposure odds ratio. 2 years
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05984992 - The First-in-human Study of SRN-001 in Healthy Participants Phase 1
Active, not recruiting NCT04312594 - Study of Jaktinib Hydrochloride Tablets in Participants With Idiopathic Pulmonary Fibrosis Phase 2
Recruiting NCT03865927 - GKT137831 in IPF Patients With Idiopathic Pulmonary Fibrosis Phase 2
Completed NCT03979430 - Early Detection of Acute Exacerbation in Patients With Idiopathic Lung Fibrosis - a Pilot Study N/A
Enrolling by invitation NCT04905693 - Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis Phase 3
Not yet recruiting NCT06241560 - A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood Phase 2
Terminated NCT04419558 - Zephyrus II: Efficacy and Safety Study of Pamrevlumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) Phase 3
Completed NCT03725852 - A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) Phase 2
Terminated NCT03573505 - An Efficacy and Safety Study of BG00011 in Participants With Idiopathic Pulmonary Fibrosis Phase 2
Recruiting NCT04148157 - Quality of Life in IPF - Patient and Physician Perceptions
Completed NCT03222648 - Structured Exercise Training Programme in Idiopathic Pulmonary Fibrosis N/A
Not yet recruiting NCT06422884 - A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) Phase 2
Completed NCT02257177 - RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients Phase 1/Phase 2
Completed NCT02268981 - Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF) N/A
Withdrawn NCT01524068 - A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations Phase 2
Enrolling by invitation NCT01382368 - Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients Phase 4
Completed NCT01110694 - Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study
Completed NCT01199887 - Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis Phase 1
Active, not recruiting NCT02951416 - Clinical Course of Interstitial Lung Diseases: European IPF Registry and Biobank
Terminated NCT00981747 - Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis Phase 2/Phase 3

External Links